Citius Pharmaceuticals to Present at the Dawson James 2017 Small Cap Growth Stock Conference

CRANFORD, N.J., Oct. 17, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, announced today that its Chief Executive Officer, Mr. Myron Holubiak, will present at the Dawson James 2017 Small Cap Growth Stock Conference.  The Conference will be held on October 19, 2017 at the Wyndham Grand Hotel in Jupiter, Florida.

Event:  Dawson James 2017 Small Cap Growth Stock Conference
Location: Wyndham Grand Hotel, Jupiter, Florida
Date: October 19, 2017 at 1:30 pm.

During the conference, Chief Executive Officer, Mr. Myron Holubiak will deliver the Company's corporate presentation and discuss recent business highlights. Management will also be available for one-on-one meetings. To arrange a meeting with management, please contact Mr. Andrew Scott: [email protected].

About Dawson James, Inc.

Dawson James Securities, a member of FINRA/SIPC, is a full service investment bank headquartered in Boca Raton, FL. The company has set out to create the highest-quality, full service investment firm specializing in the complex and fast-moving healthcare, biotechnology, technology and clean-tech sectors. For more information, please visit;  http://www.dawsonjames.com.

About Citius Pharmaceuticals, Inc.

Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients.  We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs.  By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. We focus on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches. www.citiuspharma.com

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius.  You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. 

For additional information, please contact:

Andrew Scott                                                            
Vice President, Corporate Development                                                               
908 967 6677; [email protected]

SOURCE Citius Pharmaceuticals, Inc.